{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:15:25Z","timestamp":1790198125392,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00203-024-04181-3","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:04:15Z","timestamp":1730797455000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug resistance and possible therapeutic options against influenza A virus infection over past years"],"prefix":"10.1007","volume":"206","author":[{"given":"Muhammad Asif","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Awais","family":"Ashraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"4181_CR1","doi-asserted-by":"crossref","unstructured":"Abed Y, Boivin G (2017) A review of clinical influenza A and B infections with reduced susceptibility to both oseltamivir and zanamivir. In: Open forum infectious diseases. Oxford University Press US","DOI":"10.1093\/ofid\/ofx105"},{"key":"4181_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3389\/fmicb.2016.00450","volume":"7","author":"MM Alame","year":"2016","unstructured":"Alame MM, Massaad E, Zaraket H (2016a) Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections. Front Microbiol 7:450","journal-title":"Front Microbiol"},{"issue":"8","key":"4181_CR3","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1128\/JVI.03123-12","volume":"87","author":"MJ Amorim","year":"2013","unstructured":"Amorim MJ, Kao RY, Digard P (2013) Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J Virol 87(8):4694\u20134703","journal-title":"J Virol"},{"issue":"11","key":"4181_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11051-023-05867-3","volume":"25","author":"F Araste","year":"2023","unstructured":"Araste F, Bakker AD, Zandieh-Doulabi B (2023) Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. J Nanopart Res 25(11):229","journal-title":"J Nanopart Res"},{"key":"4181_CR5","doi-asserted-by":"publisher","unstructured":"Ashraf MA et al (2024) A comprehensive review of influenza B virus, its biological and clinical aspects. Front Microbiol 15. https:\/\/doi.org\/10.3389\/fmicb.2024.1467029","DOI":"10.3389\/fmicb.2024.1467029"},{"issue":"3","key":"4181_CR6","doi-asserted-by":"publisher","first-page":"216a","DOI":"10.1016\/j.bpj.2010.12.1392","volume":"100","author":"H Badani","year":"2011","unstructured":"Badani H et al (2011) Mechanism and action of flufirvitide, a peptide inhibitor of influenza virus infection. Biophys J 100(3):216a","journal-title":"Biophys J"},{"issue":"4","key":"4181_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/v13040624","volume":"13","author":"Y Bai","year":"2021","unstructured":"Bai Y et al (2021) Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance. Viruses 13(4):624","journal-title":"Viruses"},{"key":"4181_CR8","doi-asserted-by":"crossref","unstructured":"Bai Y et al (2021) Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance. Viruses 13(4)","DOI":"10.3390\/v13040624"},{"issue":"1","key":"4181_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3390\/microorganisms11010183","volume":"11","author":"S Batool","year":"2023","unstructured":"Batool S, Chokkakula S, Song M-S (2023) Influenza treatment: limitations of antiviral therapy and advantages of drug combination therapy. Microorganisms 11(1):183","journal-title":"Microorganisms"},{"issue":"23","key":"4181_CR10","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1056\/NEJMc0910060","volume":"361","author":"M Baz","year":"2009","unstructured":"Baz M et al (2009) Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 361(23):2296\u20132297","journal-title":"N Engl J Med"},{"key":"4181_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.biomaterials.2017.05.028","volume":"138","author":"S Bhatia","year":"2017","unstructured":"Bhatia S et al (2017) Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo. Biomaterials 138:22\u201334","journal-title":"Biomaterials"},{"issue":"10","key":"4181_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"Y Boriskin","year":"2008","unstructured":"Boriskin Y et al (2008) Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem 15(10):997\u20131005","journal-title":"Curr Med Chem"},{"issue":"1","key":"4181_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/jmv.22234","volume":"84","author":"MJ Brooks","year":"2012","unstructured":"Brooks MJ et al (2012) Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol 84(1):170\u2013181","journal-title":"J Med Virol"},{"key":"4181_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105280","volume":"200","author":"SK Brown","year":"2022","unstructured":"Brown SK et al (2022) Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors. Antiviral Res 200:105280","journal-title":"Antiviral Res"},{"key":"4181_CR15","doi-asserted-by":"publisher","unstructured":"Bullard BL, Weaver EA (2021) Strategies targeting hemagglutinin as a universal influenza vaccine. Vaccines (Basel) 9(3). https:\/\/doi.org\/10.3390\/vaccines9030257","DOI":"10.3390\/vaccines9030257"},{"issue":"3","key":"4181_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003275","volume":"9","author":"S Chenavas","year":"2013","unstructured":"Chenavas S et al (2013) Monomeric nucleoprotein of influenza A virus. PLoS Pathog 9(3):e1003275","journal-title":"PLoS Pathog"},{"key":"4181_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/irv.12317","volume":"9","author":"PY Cheng","year":"2015","unstructured":"Cheng PY et al (2015) Burden of influenza-associated deaths in the Americas, 2002\u20132008. Influenza Other Respir Viruses 9:13\u201321","journal-title":"Influenza Other Respir Viruses"},{"key":"4181_CR18","doi-asserted-by":"publisher","unstructured":"Ciancio B et al (2009) Oseltamivir-resistant influenza A (H1N1) viruses detected in Europe during season 2007\u20138 had epidemiologic and clinical characteristics similar to co-circulating susceptible A (H1N1) viruses. Eurosurveillance 14(46). https:\/\/doi.org\/10.2807\/ese.14.46.19412-en","DOI":"10.2807\/ese.14.46.19412-en"},{"issue":"1","key":"4181_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115130","volume":"28","author":"G Cihan-\u00dcst\u00fcnda\u011f","year":"2020","unstructured":"Cihan-\u00dcst\u00fcnda\u011f G et al (2020) Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones. Bioorg Med Chem 28(1):115130","journal-title":"Bioorg Med Chem"},{"issue":"97","key":"4181_CR20","doi-asserted-by":"publisher","first-page":"79433","DOI":"10.1039\/C5RA12209K","volume":"5","author":"N Delaviz","year":"2015","unstructured":"Delaviz N et al (2015) Aptamer-conjugated magnetic nanoparticles for the efficient removal of HCV particles from human plasma samples. RSC Adv 5(97):79433\u201379439","journal-title":"RSC Adv"},{"issue":"10","key":"4181_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jama.2009.294","volume":"301","author":"NJ Dharan","year":"2009","unstructured":"Dharan NJ et al (2009) Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 301(10):1034\u20131041","journal-title":"JAMA"},{"issue":"3","key":"4181_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0119115","volume":"10","author":"G Dong","year":"2015","unstructured":"Dong G et al (2015) Adamantane-resistant influenza a viruses in the world (1902\u20132013): frequency and distribution of M2 gene mutations. PLoS ONE 10(3):e0119115","journal-title":"PLoS ONE"},{"key":"4181_CR23","doi-asserted-by":"publisher","unstructured":"Dufrasne F (2021) Baloxavir marboxil: an original new drug against influenza. Pharmaceuticals (Basel) 15(1):28. https:\/\/doi.org\/10.3390\/ph15010028","DOI":"10.3390\/ph15010028"},{"key":"4181_CR24","first-page":"275","volume":"II","author":"MC Eichelberger","year":"2014","unstructured":"Eichelberger MC, Wan H (2014) Influenza neuraminidase as a vaccine antigen. Influenza Pathog Control II:275\u2013299","journal-title":"Influenza Pathog Control"},{"issue":"1","key":"4181_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrmicro3367","volume":"13","author":"AJ Eisfeld","year":"2015","unstructured":"Eisfeld AJ, Neumann G, Kawaoka Y (2015) At the centre: influenza A virus ribonucleoproteins. Nat Rev Microbiol 13(1):28\u201341","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"4181_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071230","volume":"8","author":"A Gillman","year":"2013","unstructured":"Gillman A et al (2013) Resistance mutation R292K is induced in influenza A (H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS ONE 8(8):e71230","journal-title":"PLoS ONE"},{"issue":"45","key":"4181_CR27","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill DH et al (2018a) The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci 115(45):11613\u201311618","journal-title":"Proc Natl Acad Sci"},{"issue":"45","key":"4181_CR28","doi-asserted-by":"publisher","first-page":"11613","DOI":"10.1073\/pnas.1811345115","volume":"115","author":"DH Goldhill","year":"2018","unstructured":"Goldhill DH et al (2018b) The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci USA 115(45):11613\u201311618","journal-title":"Proc Natl Acad Sci USA"},{"key":"4181_CR29","doi-asserted-by":"publisher","unstructured":"Gubareva LV et al (2019) Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons. Eur Commun Dis Bull 24(3). https:\/\/doi.org\/10.2807\/1560-7917.ES.2019.24.3.1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666"},{"issue":"1","key":"4181_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s43141-023-00581-y","volume":"21","author":"D Gupta","year":"2023","unstructured":"Gupta D, Mohan S (2023) Influenza vaccine: a review on current scenario and future prospects. J Genet Eng Biotechnol 21(1):154","journal-title":"J Genet Eng Biotechnol"},{"issue":"38","key":"4181_CR31","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.2174\/0929867324666170920165926","volume":"25","author":"J Han","year":"2018","unstructured":"Han J et al (2018) Influenza virus: small molecule therapeutics and mechanisms of antiviral resistance. Curr Med Chem 25(38):5115\u20135127","journal-title":"Curr Med Chem"},{"issue":"50","key":"4181_CR32","doi-asserted-by":"publisher","first-page":"19123","DOI":"10.1073\/pnas.0607614103","volume":"103","author":"A Harris","year":"2006","unstructured":"Harris A et al (2006) Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc Natl Acad Sci 103(50):19123\u201319127","journal-title":"Proc Natl Acad Sci"},{"key":"4181_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","volume":"58","author":"RA Hauser","year":"2019","unstructured":"Hauser RA et al (2019) Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet 58:77\u201388","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"4181_CR34","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","volume":"4","author":"A Hay","year":"1985","unstructured":"Hay A et al (1985) The molecular basis of the specific anti-influenza action of amantadine. EMBO J 4(11):3021\u20133024","journal-title":"EMBO J"},{"issue":"2","key":"4181_CR35","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","volume":"32","author":"FG Hayden","year":"2019","unstructured":"Hayden FG, Shindo N (2019) Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 32(2):176\u2013186","journal-title":"Curr Opin Infect Dis"},{"issue":"10","key":"4181_CR36","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden FG et al (2018) Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 379(10):913\u2013923","journal-title":"N Engl J Med"},{"issue":"6","key":"4181_CR37","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1002\/jmv.26670","volume":"93","author":"W He","year":"2021","unstructured":"He W et al (2021) Distribution and evolution of H1N1 influenza A viruses with adamantanes-resistant mutations worldwide from 1918 to 2019. J Med Virol 93(6):3473\u20133483","journal-title":"J Med Virol"},{"key":"4181_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00224-20","author":"EC Holmes","year":"2021","unstructured":"Holmes EC et al (2021) Understanding the impact of resistance to influenza antivirals. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/cmr.00224-20","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4181_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/irv.12794","volume":"15","author":"YH Hsieh","year":"2021","unstructured":"Hsieh YH et al (2021) Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: results from a pilot randomized controlled study. Influenza Other Respir Viruses 15(1):121\u2013131","journal-title":"Influenza Other Respir Viruses"},{"issue":"20","key":"4181_CR40","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2174\/1568026617666170224122508","volume":"17","author":"Y Hu","year":"2017","unstructured":"Hu Y et al (2017) Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr Top Med Chem 17(20):2271\u20132285","journal-title":"Curr Top Med Chem"},{"issue":"3","key":"4181_CR41","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1128\/AAC.01848-13","volume":"58","author":"L Huang","year":"2014","unstructured":"Huang L et al (2014) A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance. Antimicrob Agents Chemother 58(3):1639\u20131645","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4181_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","volume":"151","author":"IFN Hung","year":"2017","unstructured":"Hung IFN et al (2017) Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb\/III trial. Chest 151(5):1069\u20131080","journal-title":"Chest"},{"issue":"05","key":"4181_CR43","first-page":"18","volume":"5","author":"X Huo","year":"2016","unstructured":"Huo X et al (2016) Economic burden and its associated factors of hospitalized patients infected with A (H7N9) virus: a retrospective study in Eastern China, 2013\u20132014. Infect Dis Poverty 5(05):18\u201325","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"4181_CR44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.antiviral.2009.03.003","volume":"83","author":"AC Hurt","year":"2009","unstructured":"Hurt AC et al (2009) Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 83(1):90\u201393","journal-title":"Antiviral Res"},{"key":"4181_CR45","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/IDR.S105473","volume":"10","author":"M Hussain","year":"2017","unstructured":"Hussain M et al (2017) Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist 10:121\u2013134","journal-title":"Infect Drug Resist"},{"key":"4181_CR46","doi-asserted-by":"crossref","unstructured":"Hussain M et al (2017) Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist 121\u2013134","DOI":"10.2147\/IDR.S105473"},{"key":"4181_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-981-15-9109-9_16","volume-title":"Influenza: advances in diagnosis and management","author":"H Ikematsu","year":"2021","unstructured":"Ikematsu H (2021) How to use anti-influenza drugs: laninamivir octanoate. In: Fujita J (ed) Influenza: advances in diagnosis and management. Springer Singapore, Singapore, pp 161\u2013169"},{"issue":"10","key":"4181_CR48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1586\/eri.11.112","volume":"9","author":"H Ikematsu","year":"2011","unstructured":"Ikematsu H, Kawai N (2011) Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther 9(10):851\u2013857","journal-title":"Expert Rev Anti Infect Ther"},{"key":"4181_CR49","doi-asserted-by":"crossref","unstructured":"Jefferson T et al (2014) Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev (4)","DOI":"10.1002\/14651858.CD008965.pub4"},{"key":"4181_CR50","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01679-20","author":"JH Jeong","year":"2020","unstructured":"Jeong JH et al (2020) In vitro profiling of laninamivir-resistant substitutions in N3 to N9 avian influenza virus neuraminidase subtypes and their association with in vivo susceptibility. J Virol. https:\/\/doi.org\/10.1128\/jvi.01679-20","journal-title":"J Virol"},{"issue":"2","key":"4181_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"RU Kadam","year":"2017","unstructured":"Kadam RU, Wilson IA (2017) Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci 114(2):206\u2013214","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"4181_CR52","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nbt.1638","volume":"28","author":"RY Kao","year":"2010","unstructured":"Kao RY et al (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28(6):600\u2013605","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4181_CR53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12951-020-00611-8","volume":"18","author":"J Kim","year":"2020","unstructured":"Kim J et al (2020a) Porous gold nanoparticles for attenuating infectivity of influenza A virus. J Nanobiotechnol 18(1):54","journal-title":"J Nanobiotechnol"},{"key":"4181_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-020-00611-8","volume":"18","author":"J Kim","year":"2020","unstructured":"Kim J et al (2020b) Porous gold nanoparticles for attenuating infectivity of influenza A virus. J Nanobiotechnol 18:1\u201311","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"4181_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/acs.biochem.3c00536","volume":"63","author":"AJ Kohlbrand","year":"2024","unstructured":"Kohlbrand AJ et al (2024) Structural studies of inhibitors with clinically relevant influenza endonuclease variants. Biochemistry 63(3):264\u2013272","journal-title":"Biochemistry"},{"issue":"5","key":"4181_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jiac.2018.12.006","volume":"25","author":"R Kumar","year":"2019","unstructured":"Kumar R et al (2019) Iron oxide nanoparticles based antiviral activity of H1N1 influenza A virus. J Infect Chemother 25(5):325\u2013329","journal-title":"J Infect Chemother"},{"issue":"7","key":"4181_CR57","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","volume":"39","author":"T Lampejo","year":"2020","unstructured":"Lampejo T (2020) Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 39(7):1201\u20131208","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4181_CR58","doi-asserted-by":"crossref","unstructured":"LeGoff J et al (2012) I223R mutation in influenza A (H1N1) pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y","DOI":"10.1371\/journal.pone.0037095"},{"issue":"2","key":"4181_CR59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","volume":"81","author":"IA Leneva","year":"2009","unstructured":"Leneva IA et al (2009) Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol. Antiviral Res 81(2):132\u2013140","journal-title":"Antiviral Res"},{"issue":"25","key":"4181_CR60","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1021\/ja202288m","volume":"133","author":"H Leonov","year":"2011","unstructured":"Leonov H et al (2011) How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? J Am Chem Soc 133(25):9903\u20139911","journal-title":"J Am Chem Soc"},{"issue":"11","key":"4181_CR61","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/infdis\/jiv288","volume":"212","author":"AG L'Huillier","year":"2015","unstructured":"L\u2019Huillier AG et al (2015) E119D neuraminidase mutation conferring pan-resistance to neuraminidase inhibitors in an A(H1N1)pdm09 isolate from a stem-cell transplant recipient. J Infect Dis 212(11):1726\u20131734","journal-title":"J Infect Dis"},{"issue":"9","key":"4181_CR62","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.3390\/v7092850","volume":"7","author":"TC Li","year":"2015","unstructured":"Li TC, Chan MC, Lee N (2015) Clinical implications of antiviral resistance in influenza. Viruses 7(9):4929\u20134944","journal-title":"Viruses"},{"issue":"5","key":"4181_CR63","doi-asserted-by":"publisher","first-page":"e01273-23","DOI":"10.1128\/mbio.01273-23","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y et al (2023) The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs. Mbio 14(5):e01273-23","journal-title":"Mbio"},{"key":"4181_CR64","doi-asserted-by":"publisher","unstructured":"Li Y et al (2021) Potentiation of recombinant NP and M1-induced cellular immune responses and protection by physical radiofrequency adjuvant. Vaccines (Basel) 9(12):1382. https:\/\/doi.org\/10.3390\/vaccines9121382","DOI":"10.3390\/vaccines9121382"},{"issue":"3","key":"4181_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13276","volume":"18","author":"CML Lim","year":"2024","unstructured":"Lim CML et al (2024) Recent advances, approaches and challenges in the development of universal influenza vaccines. Influenza Other Respir Viruses 18(3):e13276","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"4181_CR66","doi-asserted-by":"publisher","first-page":"21662","DOI":"10.1038\/srep21662","volume":"6","author":"C-L Liu","year":"2016","unstructured":"Liu C-L et al (2016) Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development. Sci Rep 6(1):21662","journal-title":"Sci Rep"},{"key":"4181_CR67","volume":"5","author":"ZY Low","year":"2023","unstructured":"Low ZY et al (2023) The convergent evolution of influenza A virus: implications, therapeutic strategies and what we need to know. Curr Res Microb Sci 5:100202","journal-title":"Curr Res Microb Sci"},{"issue":"3","key":"4181_CR68","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/microorganisms11030629","volume":"11","author":"A Luceri","year":"2023","unstructured":"Luceri A et al (2023) Silver nanoparticles: review of antiviral properties, mechanism of action and applications. Microorganisms 11(3):629","journal-title":"Microorganisms"},{"key":"4181_CR69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","volume":"10","author":"JL McAuley","year":"2019","unstructured":"McAuley JL et al (2019) Influenza virus neuraminidase structure and functions. Front Microbiol 10:39","journal-title":"Front Microbiol"},{"key":"4181_CR70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","volume":"7","author":"JL McKimm-Breschkin","year":"2013","unstructured":"McKimm-Breschkin JL (2013) Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 7:25\u201336","journal-title":"Influenza Other Respir Viruses"},{"key":"4181_CR71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.antiviral.2017.11.013","volume":"149","author":"JL McKimm-Breschkin","year":"2018","unstructured":"McKimm-Breschkin JL et al (2018) Prevention and treatment of respiratory viral infections: presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV antiviral group conference. Antiviral Res 149:118\u2013142","journal-title":"Antiviral Res"},{"key":"4181_CR72","doi-asserted-by":"publisher","first-page":"1269344","DOI":"10.3389\/fcimb.2023.1269344","volume":"13","author":"C Meseko","year":"2023","unstructured":"Meseko C et al (2023) Antiviral options and therapeutics against influenza: history, latest developments and future prospects. Front Cell Infect Microbiol 13:1269344","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"4181_CR73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12929-019-0572-3","volume":"26","author":"D Mezhenskaya","year":"2019","unstructured":"Mezhenskaya D, Isakova-Sivak I, Rudenko L (2019) M2e-based universal influenza vaccines: a historical overview and new approaches to development. J Biomed Sci 26(1):76","journal-title":"J Biomed Sci"},{"issue":"11","key":"4181_CR74","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1128\/AAC.49.11.4515-4520.2005","volume":"49","author":"VP Mishin","year":"2005","unstructured":"Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49(11):4515\u20134520","journal-title":"Antimicrob Agents Chemother"},{"key":"4181_CR75","unstructured":"Mondiale de la Sant\u00e9 O, W.H. Organization (2020) Recommended composition of influenza virus vaccines for use in the 2021 southern hemisphere influenza season\u2014Composition recommand\u00e9e des vaccins antigrippaux pour la saison grippale 2021 dans l\u2019h\u00e9misph\u00e8re Sud. Weekly Epidemiological Record= Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire 95(42):497\u2013508"},{"issue":"25","key":"4181_CR76","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1056\/NEJMp058291","volume":"353","author":"A Moscona","year":"2005","unstructured":"Moscona A (2005) Oseltamivir resistance\u2014disabling our influenza defenses. N Engl J Med 353(25):2633\u20132636","journal-title":"N Engl J Med"},{"issue":"5","key":"4181_CR77","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3390\/molecules27051645","volume":"27","author":"SE Mtambo","year":"2022","unstructured":"Mtambo SE, Ugbaja SC, Kumalo HM (2022) Impact of the R292K mutation on influenza A (H7N9) virus resistance towards peramivir: a molecular dynamics perspective. Molecules 27(5):1645","journal-title":"Molecules"},{"key":"4181_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105657","volume":"216","author":"S Mu","year":"2023","unstructured":"Mu S et al (2023) The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza. Antiviral Res 216:105657","journal-title":"Antiviral Res"},{"issue":"4","key":"4181_CR79","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/irv.12728","volume":"14","author":"M Nakauchi","year":"2020","unstructured":"Nakauchi M et al (2020) Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil. Influenza Other Respir Viruses 14(4):436\u2013443","journal-title":"Influenza Other Respir Viruses"},{"issue":"2","key":"4181_CR80","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.virusres.2009.05.010","volume":"143","author":"DP Nayak","year":"2009","unstructured":"Nayak DP et al (2009) Influenza virus morphogenesis and budding. Virus Res 143(2):147\u2013161","journal-title":"Virus Res"},{"issue":"5","key":"4181_CR81","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1086\/650458","volume":"50","author":"S Ng","year":"2010","unstructured":"Ng S et al (2010) Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis 50(5):707\u2013714","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4181_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009332","volume":"5","author":"JT Nguyen","year":"2010","unstructured":"Nguyen JT et al (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS ONE 5(2):e9332","journal-title":"PLoS ONE"},{"key":"4181_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coviro.2019.01.006","volume":"35","author":"R O\u2019Hanlon","year":"2019","unstructured":"O\u2019Hanlon R, Shaw ML (2019) Baloxavir marboxil: the new influenza drug on the market. Curr Opin Virol 35:14\u201318","journal-title":"Curr Opin Virol"},{"issue":"1","key":"4181_CR84","doi-asserted-by":"publisher","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","volume":"8","author":"S Omoto","year":"2018","unstructured":"Omoto S et al (2018) Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 8(1):9633","journal-title":"Sci Rep"},{"issue":"7","key":"4181_CR85","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3201\/eid3007.240480","volume":"30","author":"MC Patel","year":"2024","unstructured":"Patel MC et al (2024) Multicountry spread of influenza A (H1N1) pdm09 viruses with reduced oseltamivir inhibition, May 2023\u2013February 2024. Emerg Infect Dis 30(7):1410","journal-title":"Emerg Infect Dis"},{"issue":"46","key":"4181_CR86","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1016\/j.vaccine.2013.09.013","volume":"31","author":"SK Peasah","year":"2013","unstructured":"Peasah SK et al (2013) Influenza cost and cost-effectiveness studies globally\u2014a review. Vaccine 31(46):5339\u20135348","journal-title":"Vaccine"},{"issue":"1","key":"4181_CR87","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/infdis\/jiq010","volume":"203","author":"A Pizzorno","year":"2011","unstructured":"Pizzorno A et al (2011) Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 203(1):25\u201331","journal-title":"J Infect Dis"},{"issue":"11","key":"4181_CR88","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1128\/AAC.02956-14","volume":"58","author":"A Pizzorno","year":"2014","unstructured":"Pizzorno A et al (2014) Evolution of oseltamivir resistance mutations in influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. Antimicrob Agents Chemother 58(11):6398\u20136405","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4181_CR89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.37901\/jcphp19-00004","volume":"66","author":"S Selvanayagam","year":"2020","unstructured":"Selvanayagam S, Kang A, Ha DR (2020) Baloxavir marboxil: a new antiviral for acute influenza. J Contemp Pharm Pract 66(4):22\u201327","journal-title":"J Contemp Pharm Pract"},{"issue":"5","key":"4181_CR90","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","volume":"5","author":"Z Shen","year":"2015","unstructured":"Shen Z, Lou K, Wang W (2015) New small-molecule drug design strategies for fighting resistant influenza A. Acta Pharm Sin B 5(5):419\u2013430","journal-title":"Acta Pharm Sin B"},{"key":"4181_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209:107512","journal-title":"Pharmacol Ther"},{"issue":"12","key":"4181_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082431","volume":"8","author":"EV Shtykova","year":"2013","unstructured":"Shtykova EV et al (2013) Structural analysis of influenza A virus matrix protein M1 and its self-assemblies at low pH. PLoS ONE 8(12):e82431","journal-title":"PLoS ONE"},{"issue":"20","key":"4181_CR93","doi-asserted-by":"publisher","first-page":"12244","DOI":"10.3390\/ijms232012244","volume":"23","author":"JM Smyk","year":"2022","unstructured":"Smyk JM et al (2022) Evolution of influenza viruses\u2014drug resistance, treatment options, and prospects. Int J Mol Sci 23(20):12244","journal-title":"Int J Mol Sci"},{"key":"4181_CR94","first-page":"204993612110630","volume":"8","author":"K Srinivasan","year":"2021","unstructured":"Srinivasan K, Rao M (2021) Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review. Ther Adv Infect Dis 8:20499361211063016","journal-title":"Ther Adv Infect Dis"},{"issue":"6","key":"4181_CR95","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2183\/pjab.88.226","volume":"88","author":"N Sriwilaijaroen","year":"2012","unstructured":"Sriwilaijaroen N, Suzuki Y (2012) Molecular basis of the structure and function of H1 hemagglutinin of influenza virus. Proc Jpn Acad Ser B Phys Biol Sci 88(6):226\u2013249","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"4181_CR96","doi-asserted-by":"publisher","unstructured":"Sun W et al (2020) Progress in the development of universal influenza vaccines. Viruses 12(9). https:\/\/doi.org\/10.3390\/v12091033","DOI":"10.3390\/v12091033"},{"issue":"11","key":"4181_CR97","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.3201\/eid2511.190757","volume":"25","author":"E Takashita","year":"2019","unstructured":"Takashita E et al (2019) Human-to-human transmission of influenza A (H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis 25(11):2108","journal-title":"Emerg Infect Dis"},{"key":"4181_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104718","volume":"175","author":"E Takashita","year":"2020","unstructured":"Takashita E et al (2020) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017\u20132018. Antiviral Res 175:104718","journal-title":"Antiviral Res"},{"issue":"8","key":"4181_CR99","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","volume":"283","author":"JJ Treanor","year":"2000","unstructured":"Treanor JJ et al (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283(8):1016\u20131024","journal-title":"JAMA"},{"issue":"3","key":"4181_CR100","first-page":"346","volume":"221","author":"T Uehara","year":"2020","unstructured":"Uehara T et al (2020) Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis 221(3):346\u2013355","journal-title":"J Infect Dis"},{"key":"4181_CR101","doi-asserted-by":"publisher","unstructured":"De Vlugt C, Sikora D, Pelchat M (2018) Insight into influenza: a virus cap-snatching. Viruses 10(11). https:\/\/doi.org\/10.3390\/v10110641","DOI":"10.3390\/v10110641"},{"issue":"2","key":"4181_CR102","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1134\/S0026893320020168","volume":"54","author":"YN Vorobjev","year":"2020","unstructured":"Vorobjev YN (2020) Design of an efficient inhibitor for the influenza A virus M2 ion channel. Mol Biol 54(2):281\u2013291","journal-title":"Mol Biol"},{"issue":"4","key":"4181_CR103","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1073\/pnas.1216526110","volume":"110","author":"J Wang","year":"2013","unstructured":"Wang J et al (2013) Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc Natl Acad Sci 110(4):1315\u20131320","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"4181_CR104","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/nyas.12462","volume":"1323","author":"RG Webster","year":"2014","unstructured":"Webster RG, Govorkova EA (2014) Continuing challenges in influenza. Ann N Y Acad Sci 1323(1):115\u2013139","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"4181_CR105","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jviromet.2011.09.003","volume":"178","author":"D-X Xiang","year":"2011","unstructured":"Xiang D-X et al (2011) Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods 178(1\u20132):137\u2013142","journal-title":"J Virol Methods"},{"issue":"12","key":"4181_CR106","doi-asserted-by":"publisher","first-page":"10223","DOI":"10.3390\/ijms241210223","volume":"24","author":"J Yang","year":"2023","unstructured":"Yang J et al (2023) Exploring the inhibitory effect of AgBiS2 nanoparticles on influenza viruses. Int J Mol Sci 24(12):10223","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4181_CR107","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/irv.12205","volume":"8","author":"H Yu","year":"2014","unstructured":"Yu H et al (2014) The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses, 2010\u20132012. Influenza Other Respir Viruses 8(1):53\u201365","journal-title":"Influenza Other Respir Viruses"},{"issue":"7240","key":"4181_CR108","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nature07720","volume":"458","author":"P Yuan","year":"2009","unstructured":"Yuan P et al (2009) Crystal structure of an avian influenza polymerase PAN reveals an endonuclease active site. Nature 458(7240):909\u2013913","journal-title":"Nature"},{"issue":"2","key":"4181_CR109","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s15010-013-0546-4","volume":"42","author":"M Zheng","year":"2014","unstructured":"Zheng M, Luo J, Chen Z (2014) Development of universal influenza vaccines based on influenza virus M and NP genes. Infection 42(2):251\u2013262","journal-title":"Infection"},{"issue":"6","key":"4181_CR110","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.celrep.2019.04.053","volume":"27","author":"W Zheng","year":"2019","unstructured":"Zheng W et al (2019) Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. Cell Rep 27(6):1875-1885.e5","journal-title":"Cell Rep"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-024-04181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-024-04181-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-024-04181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:10:19Z","timestamp":1732785019000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-024-04181-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":110,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4181"],"URL":"https:\/\/doi.org\/10.1007\/s00203-024-04181-3","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"458"}}